{"id":30862,"date":"2025-03-28T16:33:25","date_gmt":"2025-03-28T08:33:25","guid":{"rendered":"https:\/\/flcube.com\/?p=30862"},"modified":"2025-03-28T16:33:27","modified_gmt":"2025-03-28T08:33:27","slug":"cstone-pharmaceuticals-reports-2024-results-with-license-fee-growth-offsetting-drug-sales-decline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30862","title":{"rendered":"CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline"},"content":{"rendered":"\n<p>China-based CStone Pharmaceuticals (<a href=\"https:\/\/www.google.com\/finance\/quote\/2616:HKG\">HKG: 2616<\/a>) reported its 2024 financial results and recent business highlights. Revenues reached RMB 407.2 million (USD 56.1 million), a 12.2% year-on-year (YOY) decrease. This consisted of RMB 175 million (USD 24.1 million) in pharmaceutical product sales and RMB 232 million (USD 32 million) in license fee income, which surged 113.1% YOY, partially offsetting the decline in drug sales. The annual loss narrowed to RMB 91.2 million (USD 12.6 million) due to significant reductions in operating expenses.<\/p>\n\n\n\n<p><strong>Financial Performance<\/strong><br>The company experienced a decline in pharmaceutical product sales but saw substantial growth in license fee income. This growth in licensing revenue helped mitigate the impact of reduced drug sales, reflecting CStone&#8217;s strategic emphasis on partnerships and collaborations.<\/p>\n\n\n\n<p><strong>Research and Development Pipeline<\/strong><br>CStone boasts a robust pre-clinical pipeline with over nine candidate drugs, all holding global rights. These candidates include multi-specific antibodies, antibody drug conjugates (ADCs), and radiolabeled drug conjugates (RDCs) targeting oncology, autoimmune diseases, metabolic diseases, and other areas.<\/p>\n\n\n\n<p><strong>ADC Technology Platform<\/strong><br>The company has developed an internal ADC technology platform, enabling the creation of multiple ADC products. Notable candidates include CS5007 (dual targeting EGFR and HER3), CS5005 (targeting SSTR2), CS5008 (dual targeting DLL3 and SSTR2), and CS5006 (targeting ITGB4), highlighting CStone&#8217;s innovation in oncology and beyond.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based CStone Pharmaceuticals (HKG: 2616) reported its 2024 financial results and recent business highlights. Revenues&#8230;<\/p>\n","protected":false},"author":1,"featured_media":30863,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[188,27,856],"class_list":["post-30862","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-cstone-pharmaceuticals","tag-finanical-reports","tag-hkg-2616"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based CStone Pharmaceuticals (HKG: 2616) reported its 2024 financial results and recent business highlights. Revenues reached RMB 407.2 million (USD 56.1 million), a 12.2% year-on-year (YOY) decrease. This consisted of RMB 175 million (USD 24.1 million) in pharmaceutical product sales and RMB 232 million (USD 32 million) in license fee income, which surged 113.1% YOY, partially offsetting the decline in drug sales. The annual loss narrowed to RMB 91.2 million (USD 12.6 million) due to significant reductions in operating expenses.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30862\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline\" \/>\n<meta property=\"og:description\" content=\"China-based CStone Pharmaceuticals (HKG: 2616) reported its 2024 financial results and recent business highlights. Revenues reached RMB 407.2 million (USD 56.1 million), a 12.2% year-on-year (YOY) decrease. This consisted of RMB 175 million (USD 24.1 million) in pharmaceutical product sales and RMB 232 million (USD 32 million) in license fee income, which surged 113.1% YOY, partially offsetting the decline in drug sales. The annual loss narrowed to RMB 91.2 million (USD 12.6 million) due to significant reductions in operating expenses.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30862\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-28T08:33:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-28T08:33:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2815-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30862#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30862\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline\",\"datePublished\":\"2025-03-28T08:33:25+00:00\",\"dateModified\":\"2025-03-28T08:33:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30862\"},\"wordCount\":216,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30862#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2815-png.webp\",\"keywords\":[\"CStone Pharmaceuticals\",\"Finanical Reports\",\"HKG: 2616\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30862#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30862\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30862\",\"name\":\"CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30862#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30862#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2815-png.webp\",\"datePublished\":\"2025-03-28T08:33:25+00:00\",\"dateModified\":\"2025-03-28T08:33:27+00:00\",\"description\":\"China-based CStone Pharmaceuticals (HKG: 2616) reported its 2024 financial results and recent business highlights. Revenues reached RMB 407.2 million (USD 56.1 million), a 12.2% year-on-year (YOY) decrease. This consisted of RMB 175 million (USD 24.1 million) in pharmaceutical product sales and RMB 232 million (USD 32 million) in license fee income, which surged 113.1% YOY, partially offsetting the decline in drug sales. The annual loss narrowed to RMB 91.2 million (USD 12.6 million) due to significant reductions in operating expenses.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30862#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30862\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30862#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2815-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2815-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30862#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline - Insight, China&#039;s Pharmaceutical Industry","description":"China-based CStone Pharmaceuticals (HKG: 2616) reported its 2024 financial results and recent business highlights. Revenues reached RMB 407.2 million (USD 56.1 million), a 12.2% year-on-year (YOY) decrease. This consisted of RMB 175 million (USD 24.1 million) in pharmaceutical product sales and RMB 232 million (USD 32 million) in license fee income, which surged 113.1% YOY, partially offsetting the decline in drug sales. The annual loss narrowed to RMB 91.2 million (USD 12.6 million) due to significant reductions in operating expenses.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30862","og_locale":"en_US","og_type":"article","og_title":"CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline","og_description":"China-based CStone Pharmaceuticals (HKG: 2616) reported its 2024 financial results and recent business highlights. Revenues reached RMB 407.2 million (USD 56.1 million), a 12.2% year-on-year (YOY) decrease. This consisted of RMB 175 million (USD 24.1 million) in pharmaceutical product sales and RMB 232 million (USD 32 million) in license fee income, which surged 113.1% YOY, partially offsetting the decline in drug sales. The annual loss narrowed to RMB 91.2 million (USD 12.6 million) due to significant reductions in operating expenses.","og_url":"https:\/\/flcube.com\/?p=30862","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-28T08:33:25+00:00","article_modified_time":"2025-03-28T08:33:27+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2815-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30862#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30862"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline","datePublished":"2025-03-28T08:33:25+00:00","dateModified":"2025-03-28T08:33:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30862"},"wordCount":216,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30862#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2815-png.webp","keywords":["CStone Pharmaceuticals","Finanical Reports","HKG: 2616"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30862#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30862","url":"https:\/\/flcube.com\/?p=30862","name":"CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30862#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30862#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2815-png.webp","datePublished":"2025-03-28T08:33:25+00:00","dateModified":"2025-03-28T08:33:27+00:00","description":"China-based CStone Pharmaceuticals (HKG: 2616) reported its 2024 financial results and recent business highlights. Revenues reached RMB 407.2 million (USD 56.1 million), a 12.2% year-on-year (YOY) decrease. This consisted of RMB 175 million (USD 24.1 million) in pharmaceutical product sales and RMB 232 million (USD 32 million) in license fee income, which surged 113.1% YOY, partially offsetting the decline in drug sales. The annual loss narrowed to RMB 91.2 million (USD 12.6 million) due to significant reductions in operating expenses.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30862#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30862"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30862#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2815-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2815-png.webp","width":1080,"height":608,"caption":"CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30862#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2815-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30862"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30862\/revisions"}],"predecessor-version":[{"id":30864,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30862\/revisions\/30864"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30863"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30862"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30862"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}